Spruce biosciences reports second quarter 2022 financial results and provides corporate update

San francisco--(business wire)--spruce biosciences, inc. (nasdaq: sprb), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today reported financial results for the second quarter ended june 30, 2022 and provided corporate updates. “throughout the second quarter of 2022, we continued to remain focused on clinical study execution. we were pleased to have recently surpassed 25% enrollme
SPRB Ratings Summary
SPRB Quant Ranking